Literature DB >> 9664135

Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.

J R Grandis1, Q Zeng, S D Drenning, D J Tweardy.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is frequently characterized by mutation of the p53 tumor suppressor gene and increased expression of the epidermal growth factor receptor (EGFR). To determine the potential link between p53 and EGFR expression, we examined the effect of overexpressing wild-type p53 on EGFR mRNA levels in HNSCC. In these studies, a temperature-sensitive (ts) p53 mutant was transfected into an HNSCC line which contained a deletion of one allele of the p53 gene and a mutation of the remaining allele. Following selection, six clones were isolated, characterized by Southern blot analysis, and stable expression of mutant p53 protein was confirmed by immunoblotting of clones grown at the mutant temperature. Total RNA was isolated from transfectants grown at both wild-type or mutant temperatures followed by Northern blot analysis to determine levels of EGFR mRNA expression at the two p53 conformations. Clones grown at the wild-type temperature (32.5 degreesC) demonstrated a 69% 13% decrease in EGFR mRNA compared with the same cells grown at the mutant temperature (39.5 degreesC; p=0.006) indicating that restoration of wild-type p53 reduces EGFR mRNA levels in this HNSCC cell line. These findings suggest that abnormalities in p53 may contribute to activation of EGFR gene transcription.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664135     DOI: 10.3892/ijo.13.2.375

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

2.  Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.

Authors:  Gang Niu; Xilin Sun; Qizhen Cao; Donald Courter; Albert Koong; Quynh-Thu Le; Sanjiv Sam Gambhir; Xiaoyuan Chen
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

3.  Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.

Authors:  A Hoeben; D Martin; P M Clement; J Cools; J S Gutkind
Journal:  Int J Cancer       Date:  2012-08-28       Impact factor: 7.396

Review 4.  ErbB receptors in the biology and pathology of the aerodigestive tract.

Authors:  Sarah Morgan; Jennifer R Grandis
Journal:  Exp Cell Res       Date:  2008-08-23       Impact factor: 3.905

5.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

Authors:  Y Nobuhara; N Onoda; Y Yamashita; M Yamasaki; K Ogisawa; T Takashima; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

Review 6.  Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?

Authors:  Samuel C Wagner; Thomas E Ichim; Hong Ma; Julia Szymanski; Jesus A Perez; Javier Lopez; Vladimir Bogin; Amit N Patel; Francisco M Marincola; Santosh Kesari
Journal:  J Transl Med       Date:  2015-10-29       Impact factor: 5.531

7.  EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma.

Authors:  Oliver Bissinger; Andreas Kolk; Enken Drecoll; Melanie Straub; Christina Lutz; Klaus-Dietrich Wolff; Carolin Götz
Journal:  Exp Ther Med       Date:  2017-09-18       Impact factor: 2.447

Review 8.  Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives.

Authors:  Andrea Alberti; Paolo Bossi
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 9.  Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.

Authors:  Matthew L Hedberg; Corbett T Berry; Ata S Moshiri; Yan Xiang; Christopher J Yeh; Cem Attilasoy; Brian C Capell; John T Seykora
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.